Skip to main content
. Author manuscript; available in PMC: 2015 Apr 21.
Published in final edited form as: J Immunol. 2011 Jul 8;187(4):1634–1642. doi: 10.4049/jimmunol.1100077

FIGURE 2.

FIGURE 2

Low dose of 4-1BB stimulation together with PD-L1 blockade results in a permanent increase in virus-specific CD8 T cells. A, Experimental set-up. Mice received CD4-depleting Ab (GK1.5) the day before and the day of infection with LCMV clone 13. After 45 d, mice received a single dose of anti–4-1BB agonistic Abs (50 μg) together with 200 μg PD-L1–blocking Abs at day 1. PD-L1 blockade alone was continued every 3 d (five times). B, Percentage of splenic CD8 T cells that are specific for the LCMV immunodominant Dbgp276–286 epitope at the indicated times after start of Ab treatment. C, Total numbers of splenic CD8 T cells that are specific for the LCMV immunodominant Dbgp276–286 epitope at the indicated times after start of Ab treatment. D, Serum LCMV titers. *p < 0.05. Bars indicate SEM; n = 15–21; experiments were repeated six times.